ARAshley Marie Regazzi

Ashley Marie Regazzi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ashley Marie Regazzi has a total of 244 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Data from Automated Imaging as an Adjunct to Serum and Clinical Biomarkers: A New Validated Prediction Tool for Metastatic Castration-Resistant Prostate Cancer

    by Michael J. Morris, Jessica Flynn, Binsheng Zhao, Aseem Anand, Karl Sjöstrand, Steven M. Larson, Ashley M. Regazzi, Gary V. Borzillo, Autumn Park, Lawrence H. Schwartz, et al.

    Purpose:Contemporary prostate cancer prognostic models do not include imaging and generally are based on pretreatment parameters. We sought to develop an externally validated model that used novel quantification of soft-tissue and bone disease, integrated with standard clinical and serum biomarkers, at baseline and up to 6 months of treatment.Experimental Design:Two randomized phase 3 trials, Cougar COU-AA-302 (NCT00887198; for derivation) and Alliance A031201 (NCT01949337; for validation), were used to evaluate the added value of early on-treatment bone imaging and more than 1,000 radiomics features on CT, used in conjunction with clinical and serum biomarkers in first-line metastatic castration-resistant prostate cancer. Predictive accuracy measures were computed to determine whether these early on-treatment biomarkers could reliably sort patients into risk groups that inform overall survival (OS) and whether the patient-specific biomarker risk score could precisely predict their OS time.Results:Imaging improved patient risk stratification but did not improve individual survival predictions. The strongest risk prediction model was developed for patients with bone-only metastases. This model was also the least complex, relying on just 16 risk factors, whereas all other models were high-dimensional, incorporating approximately 1,100 intercept and 1,100 slope features from the early on-treatment biomarker trajectories.Conclusions:Pretreatment and early on-treatment serum and automated quantitative imaging markers can well discriminate risk of death. Imaging improves this risk categorization relative to serum biomarkers alone. Such models can give early outcome predictions and can be used in future trials that involve imaging, even using traditional techniques such as bone scintigraphy.

  • Open Access

    Supplementary Data and Methods 1 from Automated Imaging as an Adjunct to Serum and Clinical Biomarkers: A New Validated Prediction Tool for Metastatic Castration-Resistant Prostate Cancer

    by Michael J. Morris, Jessica Flynn, Binsheng Zhao, Aseem Anand, Karl Sjöstrand, Steven M. Larson, Ashley M. Regazzi, Gary V. Borzillo, Autumn Park, Lawrence H. Schwartz, et al.

    Background on statistical methods applied and the results from the bone only cohort analysis.

  • Open Access

    Supplementary Data from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer

    by Brendan J. Guercio, Eugene J. Pietzak, Vignesh Ravichandran, Jie-Fu Chen, Ronak H. Shah, Vanessa Peters, Ashley M. Regazzi, Scot A. Niglio, David H. Aggen, Samuel A. Funt, et al.

    Plasma cell-free DNA sequencing data

  • Open Access

    Table S1 from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer

    by Brendan J. Guercio, Eugene J. Pietzak, Vignesh Ravichandran, Jie-Fu Chen, Ronak H. Shah, Vanessa Peters, Ashley M. Regazzi, Scot A. Niglio, David H. Aggen, Samuel A. Funt, et al.

    Representativeness of Study Participants

  • Open Access

    Supplemental Figures from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer

    by Brendan J. Guercio, Eugene J. Pietzak, Vignesh Ravichandran, Jie-Fu Chen, Ronak H. Shah, Vanessa Peters, Ashley M. Regazzi, Scot A. Niglio, David H. Aggen, Samuel A. Funt, et al.

  • Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules

    by Michal Sternschuss, Charlie White, Colleen Quinlan, Ashley Regazzi, Marwah Jihad, Jiawen Chen, Asia McCoy, William Rafelson, Andrew Laccetti, Michelle Makris, et al.

  • Quality of Informed Consent via Telemedicine Compared With In-Person for Clinical Cancer Research

    by Michal Sternschuss, Michael Lattanzi, Emily Vertosick, Mia Austria, Sené Martin, Ashley Regazzi, Michael T. Buckely, Joseph Lengfellner, Gregory J. Riely, David B. Solit, et al.

    PURPOSE: Telemedicine is increasingly used in oncology research including informed consent discussions, but data evaluating the potential impact of telemedicine on the quality of informed consent are scarce. METHODS: Consecutive patients with genitourinary malignancies who underwent informed consent discussions for biomarker (next-generation sequencing) or therapeutic (phase I to III) clinical studies at the Memorial Sloan Kettering Cancer Center were asked to complete modified versions of the validated Quality of Informed Consent (QuIC) questionnaire evaluating objective (QuIC A) and subjective (QuIC B) understanding. The method used for the informed consent discussion (in-person or telemedicine) was at the physician's discretion. QuIC scores were compared between telemedicine and in-person cohorts using separate linear regression models for QuIC A and B scores and for biomarker and therapeutic protocols. Cochran's Q was calculated to evaluate heterogeneity between biomarker and therapeutic protocols. RESULTS: Of 320 eligible patients approached between January 2021 and July 2022, 239 patients completed the QuIC questionnaires after informed consent discussion for biomarker (n = 128) or therapeutic (n = 111) protocols, conducted via telemedicine (n = 49) or in person (n = 190). We did not find evidence that telemedicine and in-person consent differed between the biomarker and therapeutic studies for either QuIC A or B (heterogeneity P = .13 and P = .5, Respectively), and so the main analyses combined both study types. There were no differences between groups for QuIC A (adjusted difference, –1.3 [95% CI, –4.6 to 1.9]; P = .4), but QuIC B scores were significantly higher for telemedicine versus in-person consent for the therapeutic cohort (adjusted difference, –5.2 [95% CI, –10.3 to –0.01]; P = .049). CONCLUSION: Our results support the use of telemedicine for informed consent discussions in clinical cancer research studies of biomarkers and clinical trials.


  • Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer

    by Brendan J. Guercio, Eugene J. Pietzak, Vignesh Ravichandran, Jie-Fu Chen, Ronak H. Shah, Vanessa Peters, Ashley M. Regazzi, Scot A. Niglio, David H. Aggen, Samuel A. Funt, et al.

    Purpose: Many patients with muscle-invasive bladder cancer (MIBC) are ineligible for cisplatin-based therapy. We conducted a phase II trial of neoadjuvant nivolumab ± ipilimumab for cisplatin-ineligible patients. Patients and Methods: Patients with MIBC were enrolled in two consecutive cohorts: (i) nivolumab alone and (ii) ipilimumab/nivolumab. A third cohort with alternative dosing was planned. The primary endpoint was eligibility for cystectomy ≤60 days after last treatment. Correlative analyses were performed, with the PURE-01 trial used as an independent dataset. Results: Fifteen patients enrolled onto each cohort. In cohorts 1 and 2, 12 of 15 and eight of 15 were eligible for cystectomy within 60 days, respectively. Due to cohort 2’s failure to meet the primary endpoint, cohort 3 was not initiated. With nivolumab alone, four patients achieved <ypT2ypN0 (26%), with two pathologic complete responses (pCR; 13%). With ipilimumab/nivolumab, three achieved <ypT2ypN0 (20%), with one pCR (7%). One patient after nivolumab and two after ipilimumab/nivolumab had durable clinical complete responses (CR) without cystectomy. Twelve-month recurrence-free survival (RFS) was 79% with nivolumab [95% confidence interval (CI), 61–100] and 61% with ipilimumab/nivolumab (95% CI, 39–95). Sequencing analyses suggest that NCOR1 alterations may be associated with improved clinical outcomes. Gene expression profiling indicated a potential association between tumor-infiltrating immune cells and longer RFS (log-rank P = 0.18); this was also observed in PURE-01 (P = 0.022). Conclusions: Among cisplatin-ineligible patients with MIBC, nivolumab alone was well tolerated. Ipilimumab/nivolumab caused toxicity that delayed cystectomy. Cases of progression before cystectomy indicated insufficient efficacy of pure neoadjuvant immunotherapy for unselected patients. Despite low response rates, some patients experienced sustained clinical CR without cystectomy.


  • Automated Imaging as an Adjunct to Serum and Clinical Biomarkers: A New Validated Prediction Tool for Metastatic Castration-Resistant Prostate Cancer

    by Michael J. Morris, Jessica Flynn, Binsheng Zhao, Aseem Anand, Karl Sjöstrand, Steven M. Larson, Ashley M. Regazzi, Gary V. Borzillo, Autumn Park, Lawrence H. Schwartz, et al.

    Purpose: Contemporary prostate cancer prognostic models do not include imaging and generally are based on pretreatment parameters. We sought to develop an externally validated model that used novel quantification of soft-tissue and bone disease, integrated with standard clinical and serum biomarkers, at baseline and up to 6 months of treatment. Experimental Design: Two randomized phase 3 trials, Cougar COU-AA-302 (NCT00887198; for derivation) and Alliance A031201 (NCT01949337; for validation), were used to evaluate the added value of early on-treatment bone imaging and more than 1,000 radiomics features on CT, used in conjunction with clinical and serum biomarkers in first-line metastatic castration-resistant prostate cancer. Predictive accuracy measures were computed to determine whether these early on-treatment biomarkers could reliably sort patients into risk groups that inform overall survival (OS) and whether the patient-specific biomarker risk score could precisely predict their OS time. Results: Imaging improved patient risk stratification but did not improve individual survival predictions. The strongest risk prediction model was developed for patients with bone-only metastases. This model was also the least complex, relying on just 16 risk factors, whereas all other models were high-dimensional, incorporating approximately 1,100 intercept and 1,100 slope features from the early on-treatment biomarker trajectories. Conclusions: Pretreatment and early on-treatment serum and automated quantitative imaging markers can well discriminate risk of death. Imaging improves this risk categorization relative to serum biomarkers alone. Such models can give early outcome predictions and can be used in future trials that involve imaging, even using traditional techniques such as bone scintigraphy.


  • Relationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB 90601

    by Gopa Iyer, Woonyoung Choi, Bin Luo, Filipe Carvalho, Timothy Hanlon, Henning Reis, Brendan J. Guercio, Megan Fong, Jack Mountain, Mingxiao Feng, et al.

    PURPOSE: In urothelial carcinoma, prior studies have indicated that the basal/squamous molecular subtype and the presence of select DNA damage response (DDR) gene alterations are associated with improved benefit from cisplatin-based chemotherapy. We sought to evaluate these biomarkers in specimens from the phase III Cancer and Leukemia Group B (CALGB) 90601 trial. METHODS: We performed whole-transcriptome sequencing (n = 188) and exon capture DNA sequencing (n = 208) on pretreatment tumors from the CALGB 90601 randomized trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with treatment-naïve metastatic bladder cancer. Whole-exome sequencing (WES) was performed on tumors from 22 patients who exhibited rapid progression or durable response. Tumors were assigned to molecular subtypes using three different classifiers. Proportional hazards model was used to correlate molecular subtype with overall survival (OS) and progression-free survival (PFS), adjusting for stratification factors and treatment arm (for PFS). RESULTS: Patients with basal tumors had the shortest PFS and OS in the entire cohort. PFS was numerically longer in patients with basal tumors receiving bevacizumab. DDR gene alterations were not associated with improved outcomes. FRY , a candidate predictive biomarker of chemosensitivity identified by WES, did not confer sensitivity to cisplatin or gemcitabine in functional studies. CONCLUSION: Molecular subtype and DDR alterations did not correlate with improved outcomes in CALGB 90601. Possible explanations for these results include the small cohort size, lack of strong therapeutic effects of the treatments, genomic heterogeneity between profiled specimens and the metastatic lesions under treatment pressure, and differences in biology associated with different disease states (muscle-invasive v metastatic disease).